The Impella RP platform includes the world’s smallest percutaneous right heart mechanical circulatory support (MCS) technologies designed to help patients achieve native heart recovery. They do not ...
DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...
Physicians forced to make rapid-fire choices, with limited evidence, in acute myocardial infarction complicated by cardiogenic shock (AMICS) finally have what they’ve long been waiting for: positive ...
The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients ...
In the latest observational study to address Impella’s role—this time using a large US claims database—patients who received the percutaneous left ventricular assist device (PVAD) during high-risk PCI ...
DANVERS, Mass., March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella® heart ...
Abiomed, Inc. ABMD recently received FDA pre-market approval (PMA) for its newest right heart pump — the Impella RP with SmartAssist. The FDA has deemed the new pump as safe and effective when it ...
Another observational study has questioned whether Impella ventricular assist pumps (Abiomed) should be used in patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), at ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results